Immutep Gets a New Bull at Jefferies — Market Talk
Immutep gets a new bull at Jefferies, where analyst David Stanton sees a clearer potential development path for the biotechnology company's lead product candidate. Raising his recommendation to buy from hold, Stanton is encouraged by the Australian company's update that the early discontinuation of…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.